Electromyography (EMG) is a well-established method to quantify the PFM activity. The purpose of this study was to investigate the PFM of US and LAMs EMG variables separately by ASEA device and determine the predict value of sEMG for ASEA assessing the PFM in postmenopausal women with SUI. We obtained the EMG of US and LAMs separately by ASEA device consisted of following elements: ARP, MVC, TCP, ECP and PRP. We performed ROC curve analysis for optimal cutoff level for sEMG activation of the PFM. For 65 healthy and 67 with SUI, muscle strength was lower in SUI group according to the modified Oxford grading system by bidigital palpation. The sEMG of PFM activities were significantly lower in SUI group tested by ASEA device, especially in the MVC, TCP and ECP activities in US and LAMs. According to ROC curves, US and LAMs, especially PR and PC, except IC, have optimum predict cutoff amplitude for SUI. Our study proved that US defect and dysfunctional LAMs play an important role in the pathogenesis of SUI and separation of specific regions of US and LAMs can provide a reliable and optimized treatment strategy for the precise rehabilitation of pelvic floor muscles.

The authors have declared no competing interest.

N

Yes

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the Women’s Hospital, School of Medicine, Zhejiang University, Hangzhou, China, (protocol ID: No. IRB 20220008-R &No. IRB-20240381-R), for studies involving humans.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes